214 related articles for article (PubMed ID: 37237269)
1. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
Lin Y; Zhao Y; Chen M; Li Z; Liu Q; Chen J; Ding Y; Ding C; Ding Y; Qi C; Zheng L; Li J; Zhang R; Zhou J; Wang L; Zhang QQ
BMC Cancer; 2023 May; 23(1):479. PubMed ID: 37237269
[TBL] [Abstract][Full Text] [Related]
2. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
[TBL] [Abstract][Full Text] [Related]
3. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
4. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.
Zhou JY; Yang RR; Chang J; Song J; Fan ZS; Zhang YH; Lu CH; Jiang HL; Zheng MY; Zhang SL
Acta Pharmacol Sin; 2023 Feb; 44(2):475-485. PubMed ID: 35918411
[TBL] [Abstract][Full Text] [Related]
5. EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer.
Li Z; Liu Q; Cai Y; Ye N; He Z; Yao Y; Ding Y; Wang P; Qi C; Zheng L; Wang L; Zhou J; Zhang QQ
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167114. PubMed ID: 38447883
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models.
Rathinavelu A; Kanagasabai T; Dhandayuthapani S; Alhazzani K
Oncol Rep; 2018 Apr; 39(4):1711-1724. PubMed ID: 29436685
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
Wang LL; Li JJ; Zheng ZB; Liu HY; Du GJ; Li S
Eur J Pharmacol; 2004 Oct; 502(1-2):1-10. PubMed ID: 15464084
[TBL] [Abstract][Full Text] [Related]
8. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
9. BH4 domain of Bcl-2 as a novel target for cancer therapy.
Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
[TBL] [Abstract][Full Text] [Related]
10. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.
Gabellini C; Trisciuoglio D; Del Bufalo D
Carcinogenesis; 2017 Jun; 38(6):579-587. PubMed ID: 28203756
[TBL] [Abstract][Full Text] [Related]
11. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.
Akl H; Vervloessem T; Kiviluoto S; Bittremieux M; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2240-52. PubMed ID: 24768714
[TBL] [Abstract][Full Text] [Related]
12. Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.
Chen J; Zhou Z; Yao Y; Dai J; Zhou D; Wang L; Zhang QQ
J Cell Mol Med; 2018 Oct; 22(10):4760-4770. PubMed ID: 30010249
[TBL] [Abstract][Full Text] [Related]
13. Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/ BAI1 signaling pathway.
Cao J; Liu X; Yang Y; Wei B; Li Q; Mao G; He Y; Li Y; Zheng L; Zhang Q; Li J; Wang L; Qi C
Angiogenesis; 2020 Aug; 23(3):325-338. PubMed ID: 32020421
[TBL] [Abstract][Full Text] [Related]
14. Isoindolone derivative QSN-10c induces leukemic cell apoptosis and suppresses angiogenesis via PI3K/AKT signaling pathway inhibition.
Lv WW; Qin SN; Chen CQ; Zhang JJ; Ren TS; Xu YN; Zhao QC
Acta Pharmacol Sin; 2014 May; 35(5):625-35. PubMed ID: 24786233
[TBL] [Abstract][Full Text] [Related]
15. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the anti-apoptotic mechanism of Bcl-B.
Zhai D; Ke N; Zhang H; Ladror U; Joseph M; Eichinger A; Godzik A; Ng SC; Reed JC
Biochem J; 2003 Nov; 376(Pt 1):229-36. PubMed ID: 12921534
[TBL] [Abstract][Full Text] [Related]
17. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo.
Tian F; Zhang X; Tong Y; Yi Y; Zhang S; Li L; Sun P; Lin L; Ding J
Cancer Biol Ther; 2005 Aug; 4(8):874-82. PubMed ID: 16082187
[TBL] [Abstract][Full Text] [Related]
18. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J; Deng X
Oncotarget; 2016 May; 7(19):27753-63. PubMed ID: 27049723
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
20. Prosopis juliflora (Sw.) DC phytochemicals induce apoptosis and inhibit cell proliferation signaling pathways, EMT, migration, invasion, angiogenesis and stem cell markers in melanoma cell lines.
Choudhari J; Nimma R; Nimal SK; Totakura Venkata SK; Kundu GC; Gacche RN
J Ethnopharmacol; 2023 Aug; 312():116472. PubMed ID: 37062530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]